Arbutus BiopharmaABUS.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Arbutus Biopharma (ABUS.O) trades at a P/E of 5.45x, P/B of 3.23x, P/S of 4.59x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 34th percentile over the trailing 10Y window (vs. 34th percentile over 3Y); P/B sits at the 60th percentile over the trailing 10Y window (vs. 8th percentile over 3Y); P/S sits at the 2nd percentile over the trailing 10Y window (vs. 6th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 5th percentile within its industry and the 6th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B percentiles diverge here, differing by 25.7 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Arbutus Biopharma operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: ABUS · ABUS
Want the full picture on whether Arbutus Biopharma (ABUS.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 5.45 | ||||||
| P/B (MRQ) | 3.23 | ||||||
| P/S (TTM) | 4.59 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |